Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
79 studies found for:    "Mumps"
Show Display Options
Rank Status Study
1 Completed Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
Conditions: Rubella;   Varicella;   Mumps;   Measles;   Measles-Mumps-Rubella-Varicella Vaccine
Interventions: Biological: PriorixTM;   Biological: VarilrixTM;   Biological: GSK Biologicals' vaccine 208136
2 Completed Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR Vaccine
3 Active, not recruiting Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants
Condition: Mumps
Interventions: Biological: investigational live attenuated mumps vaccine;   Biological: control live attenuated mumps vaccine
4 Completed
Has Results
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
Conditions: Japanese Encephalitis;   Measles;   Mumps;   Rubella
Intervention: Biological: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
5 Completed Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
6 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™);   Biological: Kinrix®;   Biological: Varivax®
7 Withdrawn Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
Conditions: Mumps;   Rubella;   Measles;   Varicella
Interventions: Biological: Priorix-Tetra™;   Other: Safety data collection
8 Completed Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Measles;   Rubella;   Mumps;   Varicella
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
9 Completed Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Mumps;   Rubella;   Measles;   Varicella
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
10 Completed Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Mumps;   Varicella;   Rubella;   Measles
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
11 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Conditions: Measles;   Mumps;   Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
12 Completed Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMR Bio-Manguinhos;   Biological: MMR GlaxoSmithKline
13 Completed Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Condition: Measles; Mumps; Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
14 Completed Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Conditions: Rubella;   Varicella;   Mumps;   Measles
Interventions: Biological: MeMuRu-OKA (study vac);   Biological: MMR, Varicella vacc (control)
15 Completed A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live;   Biological: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
16 Completed Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)
Conditions: Mumps;   Rubella;   Measles
Intervention: Biological: MMR (Mumps, Measles and Rubella)
17 Not yet recruiting Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine
Conditions: Encephalitis, Japanese;   Measles;   Mumps;   Rubella
Interventions: Biological: CD-JEV;   Biological: MMR
18 Completed Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MeMuRu-OKA (study vacc);   Biological: MMR, Varicella vacc (control)
19 Completed Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
Conditions: Measles;   Mumps;   Rubella;   Varicella
Intervention: Biological: V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
20 Completed
Has Results
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMRV (AMP);   Biological: MMRV (2006 process)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years